Status:
WITHDRAWN
Dopamine D-2 Antagonist Use in Poor Responders in IVF: a Randomized Controlled Trial
Lead Sponsor:
Mount Sinai Hospital, Canada
Conditions:
in Vitro Fertilization
Poor Responder
Eligibility:
FEMALE
21-43 years
Phase:
NA
Brief Summary
Metoclopramide is a dopamine D2 receptor antagonist with antiemetic and gastrokinetic properties which has been approved for use in pregnant women. Women with polycystic ovary syndrome (PCOS) have bee...
Detailed Description
Poor responders constitute a significant and challenging population of women to treat with in vitro fertilization (IVF). This population includes women who respond sub-optimally to conventional ovaria...
Eligibility Criteria
Inclusion
- Poor responders undergoing a repeat IVF cycle defined as women who have undergone at least one previous IVF cycle with fewer than 4 oocytes retrieved and at least one of the following:
- Advanced age (≥40 years) or any other risk factor for poor ovarian response
- Abnormal ovarian reserve testing (antral follicle count (AFC) \< 5-7 or anti-mullerian hormone (AMH) level \< 3.6-7.9 pmol/L)
Exclusion
- Subjects who have previously been recruited into this study and either had cycle cancellation, underwent retrieval or dropped out of the study.
- Women with contraindications or allergies to metoclopramide.
- Women with elevated prolactin levels or known to have pituitary microadenomas or macroadenoma.
- Women who are taking dopamine agonist medications.
Key Trial Info
Start Date :
March 1 2016
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2018
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT02262923
Start Date
March 1 2016
End Date
March 1 2018
Last Update
April 11 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Mount Sinai Hospital
Toronto, Ontario, Canada, M5T 3H7